Immunesensor Therapeutics

ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase)- STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian "James" Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy. There are also multiple new drug candidates emerging from the company research, including an exciting cGAS inhibitor program designed to suppress overactivated autoimmunity.